Report
EUR 13.72 For Business Accounts Only

KOBAYASHI PHARMACEUTICAL sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of KOBAYASHI PHARMACEUTICAL (JP), active in the Nondurable Household Products industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date January 18, 2022, the closing price was JPY 8,610.00 and its target price was estimated at JPY 7,966.78.
Underlying
Kobayashi Pharmaceutical Co. Ltd.

Kobayashi Pharmaceutical is the parent company of a group mainly engaged in the manufacture and sale of deodorizing air fresheners, pharmaceuticals, oral hygiene products and other products, as well as the import and market of medical devices for use in medical. Co.'s principal business segments are domestic consumer products business, overseas consumer products business, and mail-order business. Co.'s principal products are pharmaceuticals, oral hygiene products, sanitary products, deodorizing air fresheners, household sundries, food products, body warmers, and others. Co. also provides food products and skincare products, collagen, face cream and hair tonic with aloe through mail order.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch